Vietnam Product

VERTISUM

Vertisum Tablets

Vertisum Tablets

Why you have been prescribed this medicine?

You have been prescribed this medicine if you have any of the following:
Vertigo due to Meniere's syndrome, labyrinthis and other causes, and for nausea and vomiting from whatever cause including that associated with migraine. It may also be used for schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short-term management of anxiety.

When you should consult your doctor?

You should consult your doctor if you experience any of the following:

Generally, adverse reactions occur at a low frequency; the most common reported adverse reactions are nervous system disorders.

What to do if you miss a dose?

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.
Otherwise take it as soon as you remember and then go back to taking it as you would normally.

Things you MUST NOT DO while on this medicine?

Known hypersensitivity to prochlorperazine or to any of the other ingredients.

What to do if you accidentally take too much (overdose) of the medicine?

Symptoms of phenothiazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias and hypothermia. Severe extrapyramidal dyskinesias may occur.
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Generalised vasodilatation may result in circulatory collapse; raising the patient's legs may suffice. In severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.
Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstrictor agents are not generally recommended. Avoid the use of adrenaline.
Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life threatening, appropriate anti-arrhythmic therapy may be considered.
Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.
Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions usually respond to procyclidine (5-10 mg) or orphenadrine (20-40 mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.
Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.

Is it safe in pregnancy and breast-feeding?

Tell your doctor immediately if you become pregnant while taking this medication.
For safety of any drug during pregnancy or breastfeeding – please consult your doctor.

Storage Conditions:

STORAGE CONDITION:
Store below 30°C in dry place. Protect from light.

DOSAGE FORMS AND PACKING AVAILABLE:
Tablets
Vertisum Tablets are supplied in Aluminium-PVC/PVDC blister packs of 10 tablets. 1 or 10 such blisters are packed in a carton box alongwith pack insert.

SHELF- LIFE:
3 years

NAME AND ADDRESS OF MANUFACTURER:
Kusum Healthcare Pvt. Ltd.
SP 289(A), RIICO Industrial Area,
Chopanki, Bhiwadi (Raj.),
India.
DATE OF REVISION OF PACKAGE INSERT: Not Applicable

Drug Description

Composition:
Each uncoated tablet contains:
Prochlorperazine Maleate BP……………5 mg

Additional Excipients:
Lactose monohydrate (Pharmatose 200 M), Microcrystalline Cellulose (PH101), Microcrystalline Cellulose (PH102), Maize Starch, Croscarmellose sodium, Sodium lauryl Sulphate, Magnesium Stearate, Colloidal silicon dioxide and purified water.

Indications and dosage.

INDICATIONS:
Vertigo due to Meniere's syndrome, labyrinthis and other causes, and for nausea and vomiting from whatever cause including that associated with migraine. It may also be used for schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short-term management of anxiety.

ADMINISTRATION AND DOSAGE:
Adult
Indication
Dosage
Prevention of nausea and vomiting 5 to 10 mg b.d. or t.d.s.
Treatment of nausea and vomiting 20 mg stat, followed if necessary by 10 mg two hours later.
Vertigo and Meniere's syndrome 5 mg t.d.s. increasing if necessary to a total of 30 mg daily. After several weeks dosage may be reduced gradually to 5-10 mg daily. Adjunct in the short term
management of anxiety
15-20 mg daily in divided doses initially but this may be increased if necessary to a maximum of 40 mg daily in divided doses.
Schizophrenia and other psychotic

disorders
Usual effective daily oral dosage is in the order of 75-100 mg daily. Patients vary widely in response. The following schedule is suggested: Initially 12.5 mg twice daily for 7 days, the daily amount being subsequently increased 12.5 mg at 4 to 7 days interval until a satisfactory response is obtained. After some weeks at the effective dosage, an attempt should be made reduce this dosage. Total daily amounts as small as 50 mg or even 25 mg have sometimes been found to be effective.

Children
Indication Dosage Prevention and treatment of nausea and vomiting If it is considered unavoidable to use Prochlorperazin for a child, the dosage is 0.25 mg/kg bodyweight two or three a day. Prochlorperazine tablets is not recommended for children weighing less than 10 Kg or below 1 year of age. A lower dose is recommended.

Side effects and drug interactions.

SIDE EFFECTS:
Generally, adverse reactions occur at a low frequency; the most common reported adverse reactions are nervous system disorders.

ADVERSE EFFECTS:
Blood and lymphatic system disorders: A mild leukopenia occurs in up to 30% of patients on prolonged high dosage. Agranulocytosis may occur rarely: it is not dose related.

Endocrine:
Hyperprolactinaemia which may result in galactorrhoea, gynaecomastia, amenorrhoea; impotence.

Nervous system disorders:
Acute dystonia or dyskinesias, usually transitory are commoner in children and young adults, and usually occur within the first 4 days of treatment or after dosage increases. Akathisia characteristically occurs after large initial doses.

Parkinsonism is more common in adults and the elderly. It usually develops after weeks or months of treatment. One or more of the following may be seen: tremor, rigidity, akinesia or other features of Parkinsonism. Commonly just tremor.

Tardive dyskinesia:
If this occurs it is usually, but not necessarily, after prolonged or high dosage. It can even occur after treatment has been stopped. Dosage should therefore be kept low whenever possible.

Insomnia and agitation may occur.
Eye disorders:
Ocular changes and the development of metallic greyish-mauve coloration of exposed skin have been noted in some individuals mainly females, who have received chlorpromazine continuously for long periods (four to eight years). This could possibly happen with Vertisum.
Cardiac disorders:
ECG changes include QT prolongation (as with other neuroleptics), ST depression, U-Wave and T-Wave changes. Cardiac arrhythmias, including ventricular arrhythmias and atrial arrhythmias, A-V block, ventricular tachycardia, which may result in ventricular fibrillation or cardiac arrest have been reported during neuroleptic phenothiazine therapy, possibly related to dosage. Pre-existing cardiac disease, old age, hypokalaemia and concurrent tricyclic antidepressants may predispose. There have been isolated reports of sudden death, with possible causes of cardiac origin, as well as cases of unexplained sudden death, in patients receiving neuroleptic phenothiazines.

Vascular disorders:
Hypotension, usually postural, commonly occurs. Elderly or volume depleted subjects are particularly susceptible; it is more likely to occur after intramuscular injection. Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs – Frequency unknown Gastrointestinal disorders: dry mouth may occur.

Respiratory, thoracic and mediastinal disorders:
Respiratory depression is possible in susceptible patients. Nasal stuffiness may occur.

Hepato-biliary disorders:
Jaundice, usually transient, occurs in a very small percentage of patients taking neuroleptics. A premonitory sign may be sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Neuroleptic jaundice has the biochemical and other characteristics of obstructive jaundice and is associated with obstruction of the canaliculi by bile thrombi; the frequent presence of an accompanying eosinphilia indicates the allergic nature of this phenomenon. Treatment should be withheld on the development of jaundice.

Skin and subcutaneous tissue disorders: Contact skin sensitisation may occur rarely in those frequently handling preparations of certain phenothiazines. Skin rashes of various kinds may also be seen in patients treated with the drug. Patients on high dosage should be warned that they may develop photosensitivity in sunny weather and should avoid exposure to direct sunlight.

General disorders and administration site conditions:
Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) may occur with any neuroleptic. Intolerance to glucose, hyperglycaemia.

Pregnancy, puerperium and perinatal conditions; drug withdrawal syndrome neonatal – Frequency not known.

ADVERSE DRUG REACTION*:
"Inform doctors about unexpected reactions after using drugs".

DRUG INTERACTIONS:
Adrenaline must not be used in patients overdosed with Vertisum.
The CNS depressant actions of neuroleptic agents may be intensified (additively) by alcohol, barbiturates and other sedatives. Respiratory depression may occur. Anticholinergic agents may reduce the antipsychotic effect of neuroleptics and the mild anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs, possibly leading to constipation, heat stroke, etc.

Some drugs interfere with absorption of neuroleptic agents:
Antacids, anti-Parkinson drugs and lithium.

Where treatment for neuroleptic-induced extrapyramidal symptoms is required, anticholinergic antiparkinsonian agents should be used in preference to levodopa, since neuroleptics antagonise the antiparkinsonian action of dopaminergics.

High doses of neuroleptics reduce the response to hypoglycaemic agents, the dosage of which might have to be raised.
The hypotensive effect of most antihypertensive drugs especially alpha adrenoceptor blocking agents may be exaggerated by neuroleptics.
The action of some drugs may be opposed by phenothiazine neuroleptics; these include amfetamine, levodopa, clonidine, guanethidine and adrenaline.
Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol, phenobarbitals have been observed but were not of clinical significance.
Simultaneous administration of desferrioxamine and prochlorperazine has been observed to induce transient metabolic encephalopathy characterised by loss of consciousness for 48-72 hours.
There is an increased risk of arrhythmias when neuroleptics are used with concomitant QT prolonging drugs (including certain antiarrhythmics, antidepressants and other antipsychotics) and drugs causing electrolyte imbalance.
There is an increased risk of agranulocytosis when neuroleptics are used concurrently with drugs with myelosuppressive potential, such as carbamazepine or certain antibiotics and cytotoxics.
In patients treated concurrently with neuroleptics and lithium, there have been rare reports of neurotoxicity.

Warnings and precautions

PREGNANCY AND LACTATION:
There is inadequate evidence of safety in pregnancy. There is evidence of harmful effects in animals. Vertisum should be avoided in pregnancy unless the physician considers it essential. Neuroleptics may occasionally prolong labour and at such time should be withheld until the cervix is dilated 3-4 cm. possible adverse effects on the neonate include lethargy or paradoxical hyperexcitability, tremor and low apgar score.
Neonates exposed to antipsychotics (including Vertisum) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.
Consequently, newborns should be monitored carefully.
Phenothiazines may be excreted in milk;
therefore breast feeding should be suspended during treatment.

SPECIAL WARNINGS:
Vertisum should be avoided in patients with liver or renal dysfunction, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis and prostate hypertrophy. It should be avoided in patients known to be hypersensitive to phenothiazines or with a history of narrow angle glaucoma or agranulocytosis. Close monitoring is required in patients with epilepsy or a history of seizures, as phenothiazines may lower the seizure threshold. As agranulocytosis has been reported, regular monitoring of the complete blood count is recommended. The occurrence of unexplained infections or fever may be evidence of blood dyscrasia, and requires immediate haematological investigation.
It is imperative that treatment be discontinued in the event of unexplained fever, as this may be a sign of neuroleptic malignant syndrome (pallor, hyperthermia, autonomic dysfunction, altered consciousness, muscle rigidity). Signs of autonomic dysfunction, such as sweating and arterial instability, may precede the onset of hyperthermia and serve as early warning signs. Although neuroleptic malignant syndrome may be idiosyncratic in origin, dehydration and organic brain disease are predisposing factors. Acute withdrawal symptoms, including nausea, vomiting and insomnia, have very rarely been reported following the abrupt cessation of high doses of neuroleptics. Relapse may also occur, and the emergence of extrapyramidal reactions has been reported. Therefore, gradual withdrawal is advisable.
In schizophrenia, the response to neuroleptic treatment may be delayed. If treatment is withdrawn, the recurrence of symptoms may not become apparent for some time. Neuroleptic phenothiazines may potentiate QT interval prolongation which increases the risk of onset of serious ventricular arrhythmias of the torsade de pointes type, which is potentially fatal (sudden death). QT prolongation is exacerbated, in particular, in the presence of bradycardia, hypokalaemia, and congenital or acquired (i.e. drug induced) QT prolongation. The risk-benefit should be fully assessed before Vertisum treatment is commenced. If the clinical situation permits, medical and laboratory evaluations (e.g. biochemical status and ECG) should be performed to rule out possible risk factors (e.g. cardiac disease; family history of QT prolongation; metabolic abnormalities such as hypokalaemia, hypocalcaemia or hypomagnesaemia; starvation; alcohol abuse; concomitant therapy with other drugs known to prolong the QT interval) before initiating treatment with Vertisum and during the initial phase of treatment, or as deemed necessary during the treatment.
Avoid concomitant treatment with other neuroleptics.
Stroke: In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs or other populations of patients cannot be excluded. Vertisum should be used with caution in patients with stroke risk factors.
As with all antipsychotic drugs, Vertisum should not be used alone where depression is predominant. However, it may be combined with antidepressant therapy to treat those conditions in which depression and psychosis coexist.
Because of the risk of photosensitisation, patients should be advised to avoid exposure to direct sunlight.
To prevent skin sensitisation in those frequently handling preparations of phenothiazines, the greatest care must be taken to avoid contact of the drug with the skin. It should be used with caution in the elderly, particularly during very hot or very cold weather (risk of hyper-, hypothermia).
The elderly are particularly susceptible to postural hypotension.
Vertisum should be used cautiously in the elderly owing to their susceptibility to drugs acting on the central nervous system and a lower initial dosage is recommended. There is an increased risk of drug-induced Parkinsonism in the elderly particularly after prolonged use. Care should also be taken not to confuse the adverse effects of Vertisum, e.g. orthostatic hypotension, with the effects due to the underlying disorder.
Children:
Vertisum has been associated with dystonic reactions particularly after a cumulative dosage of 0.5 mg/kg. It should therefore be used cautiously in children Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. Increased Mortality in Elderly people with Dementia
Vertisum is not licensed for the treatment of dementia-related behavioural disturbances.

Overdosage and Contraindications

CONTRAINDICATIONS:
Known hypersensitivity to prochlorperazine or to any of the other ingredients.

OVERDOSE:
Symptoms of phenothiazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias and hypothermia. Severe extrapyramidal dyskinesias may occur.
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Generalised vasodilatation may result in circulatory collapse; raising the patient's legs may suffice. In severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.
Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstrictor agents are not generally recommended. Avoid the use of adrenaline.
Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life threatening, appropriate anti-arrhythmic therapy may be considered.
Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.
Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions usually respond to procyclidine (5-10 mg) or orphenadrine (20-40 mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.
Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.

Clinical pharmacology.

PHARMACEUTICAL FORM: Tablets PHARMACOTHERAPEUTIC GROUP: Antipsychotic

Code ATC:
N05AB04
Pharmacological properties:
Prochlorperazine has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and weaker anti-muscarinic properties. It inhibits dopamine and prolactin-release-inhibitory factor, thus stimulating the release of prolactin. The turnover of dopamine in the brain is increased. There is evidence that the antagonism of central dopaminergic function is related to the therapeutic effect in psychotic conditions.
Prochlorperazine has sedative properties but tolerance to the sedation usually develops rapidly. Prochlorperazine has anti-emetic, anti-pruritic, serotonin-blocking, and weak antihistamine properties and slight ganglion-blocking activity. It inhibits the heat regulating centre, can relax smooth muscle and has membrane stabilising and hence local anaesthetic properties. Its actions on the autonomic system produce vasodilatation, hypotension and tachycardia. Salivary and gastric secretions are reduced.

Pharmacokinetics:
Prochlorperazine is well absorbed from the GI tract but is subject to considerable first pass metabolism from the gut wall. It is also extensively metabolised in the liver and is excreted in the urine and bile. Plasma concentrations following oral administration are much lower than those following intramuscular injection, and are subject to wide inter-subject variation. There is no simple correlation between plasma concentrations of prochlorperazine and its metabolites, and therapeutic effect.
Prochlorperazine may be metabolised by hydroxylation and conjugation with glucuronic acid, N-oxidation, oxidation of the sulphur atom and dealkylation. Plasma half-life is reported to be only a few hours but elimination of the metabolites may be very prolonged. Prochlorperazine is extensively bound to plasma proteins, widely distributed in the body (it crosses the blood/brain barrier) and its metabolites cross the placental barrier and are excreted in milk. The rate of metabolism and excretion decreases in old age.

STORAGE CONDITION:
Store below 30°C in dry place. Protect from light.

DOSAGE FORMS AND PACKING AVAILABLE:
Tablets
Vertisum Tablets are supplied in Aluminium-PVC/PVDC blister packs of 10 tablets. 1 or 10 such blisters are packed in a carton box along with pack insert.

SHELF- LIFE:
3 years

NAME AND ADDRESS OF MANUFACTURER:
Kusum Healthcare Pvt. Ltd.
SP 289(A), RIICO Industrial Area,
Chopanki, Bhiwadi (Raj.),
India.
DATE OF REVISION OF PACKAGE INSERT: Not Applicable

CERTIFICATES

KEEP IN TOUCH

Kusum Healthcare Pvt Ltd

Regd. Office: D-158A, Okhla Industrial Area

Phase-1, New Delhi-110020, India

Tel: 011-41005147, 40514919

Fax: +91-11-40527575

Email: kusumhealth@kusumhealthcare.com

CIN: U65929DL1997PTC085780

Friend Link: Adidas Stan Smith Adidas Ultra Boost Adidas Yeezy 350 Boost Nike Air Jordan Nike Air Max 2017 Nike LeBron 14 Friend Link: Adidas NMD Runner PK Air Jordan XXXI Nike Kwazi Friend Link: Nike Roshe LD 1000 Nike Air Presto Ultra Flyknit Nike Air Max 90 Fireflies Adidas J Wall 3 Nike Flyknit Max Nike Air Max Zoom 90 Friend Link: Adidas Originals NMD Adidas Yeezy Boost 550 Adidas Tubular Schuhe Adidas Originals Pride Pack Adidas Originals Stan Smith W Adidas Originals ZX 500 Adidas Climacool Boat Lace MBT Baridi Women